Literature DB >> 19647865

Raltegravir: a new choice in HIV and new chances for research.

Sean Emery1, Alan Winston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19647865     DOI： 10.1016/S0140-6736(09)61392-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

2.  Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Authors:  Kevin M Tyo; Amanda B Lasnik; Longyun Zhang; Mohamed Mahmoud; Alfred B Jenson; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  J Control Release       Date:  2020-02-05       Impact factor: 9.776

3.  Resistance to integrase inhibitors.

Authors:  Mathieu Métifiot; Christophe Marchand; Kasthuraiah Maddali; Yves Pommier
Journal:  Viruses       Date:  2010-06-25       Impact factor: 5.048

4.  Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products.

Authors:  Miyuki Kawado; Shuji Hashimoto; Shin-Ichi Oka; Katsuyuki Fukutake; Satoshi Higasa; Hiroshi Yatsuhashi; Miwa Ogane; Manabu Okamoto; Takuma Shirasaka
Journal:  Open AIDS J       Date:  2017-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.